Dianhydrogalactitol manufacturers
- VAL-083
-
- $48.00 / 1mg
-
2024-11-04
- CAS:23261-20-3
- Min. Order:
- Purity: ≥98%
- Supply Ability: 10g
|
| | Dianhydrogalactitol Basic information |
| Product Name: | Dianhydrogalactitol | | Synonyms: | Dianhydrogalactitol;Dianhydrodulcitolum;1,2,5,6-DIANHYDRODULCITOL;1,2:5,6-Diepoxyhexane-3,4-diol;1,2-Di(oxiranyl)ethylene glycol;Dulcitol diepoxide;NSC-132313;1,2:5,6-Diepoxydulcitol | | CAS: | 23261-20-3 | | MF: | C6H10O4 | | MW: | 146.14 | | EINECS: | | | Product Categories: | APIS | | Mol File: | 23261-20-3.mol |  |
| | Dianhydrogalactitol Chemical Properties |
| Melting point | 96.5-98.5 °C | | Boiling point | 185.74°C (rough estimate) | | density | 1.567 | | refractive index | 1.4310 (estimate) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder | | pka | 13.53±0.20(Predicted) | | color | White to off-white |
| | Dianhydrogalactitol Usage And Synthesis |
| Uses | Dulcitol Diepoxide is a cytostatic drug. Dulcitol Diepoxide can be used for treatment of leukemia, lung cancer, multiple myeloma, and nasopharyngeal carcinoma. | | Biological Activity | val-083 is a bi-functional alkylating agent, with potential antitumor activity.val-083 can cross the blood brain barrier and appears to be selective for tumor cells. val-083 alkylates and crosslinks dna which ultimately inhibit the proliferation of cancer cells. val-083 does not show cross-resistance to other conventional chemotherapeutic agents. the half-life of val-083 in the brain is long. val-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors. | | in vitro | VAL-083 is an alkylating agent that creates N7 methylation on DNA. VAL-083 suppresses U251 and SF188 cell growth and induces apoptosis after 72 h. | | in vivo | VAL-083 (Dianhydrogalactitol; 25, 50, 100 μg/mL) dose-dependently inhibits angiogenesis in zebrafish model. VAL-083 considerably reduces VEGF, VEGFR2, and FGF2 expression at 25 μg/mL, and further causes reduction in FGFR2 expression at 50 μg/mL. It (1,2:5,6-dianhydrogalactitol; 5 mg/kg, iv, twice per week for 6 weeks) significantly blocks the growth of LN229 cells in mice with the relative tumor growth rate (T/C) of 22.38%, and the tumor growth inhibitory rate (TGI) of 83.58%. Moreover, VAL-083 dramatically activates the CDC25C-CDK1 cascade in the xenografted tumor moedl. | | target | DNA | | references | http://www. delmarpharma.com/product_development_programs/val083/ |
| | Dianhydrogalactitol Preparation Products And Raw materials |
|